NCT05625633 Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
| NCT ID | NCT05625633 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Western Institute for Veterans Research |
| Condition | Warts |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-03-25 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2024-03-25 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Eligibility Criteria
Inclusion Criteria: 1. Must be able to understand and provide written informed consent 2. Age 18 or older 3. Clinical diagnosis of cutaneous warts 4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.) Exclusion Criteria: 1. Untreated cutaneous warts 2. Anogenital warts 3. Oral warts 4. Treatment for cutaneous warts in the past 4 weeks 5. Active acute illness 6. Immunosuppression 7. Known hypersensitivity to HPV vaccination 8. Subjects may not receive any other investigational treatment 9. Pregnancy or planned pregnancy during the study period
Contact & Investigator
Lowell Nicholson, MD
PRINCIPAL INVESTIGATOR
University of Utah Health Care System
Frequently Asked Questions
Who can join the NCT05625633 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Warts. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05625633 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05625633 currently recruiting?
Yes, NCT05625633 is actively recruiting participants. Contact the research team at lowell.nicholson@hsc.utah.edu for enrollment information.
Where is the NCT05625633 trial being conducted?
This trial is being conducted at Salt Lake City, United States, Salt Lake City, United States.
Who is sponsoring the NCT05625633 clinical trial?
NCT05625633 is sponsored by Western Institute for Veterans Research. The principal investigator is Lowell Nicholson, MD at University of Utah Health Care System. The trial plans to enroll 120 participants.